First Header Logo Second Header Logo

Connection

Michael Shapiro to Treatment Outcome

This is a "connection" page, showing publications Michael Shapiro has written about Treatment Outcome.
Connection Strength

1.222
  1. Shapiro MD, Taub PR, Louie MJ, Lei L, Ballantyne CM. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023 Aug; 378:117182.
    View in: PubMed
    Score: 0.128
  2. Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23; 28(8):816-822.
    View in: PubMed
    Score: 0.102
  3. Shapiro MD, Maron DJ, Morris PB, Kosiborod M, Sandesara PB, Virani SS, Khera A, Ballantyne CM, Baum SJ, Sperling LS, Bhatt DL, Fazio S. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 10 15; 74(15):1926-1942.
    View in: PubMed
    Score: 0.099
  4. Kheiri B, Barbarawi M, Bachuwa G, Shapiro MD. Aspirin for Primary Prevention of Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 06; 12(6):e005846.
    View in: PubMed
    Score: 0.096
  5. Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: Current status, controversies, and future directions. Trends Cardiovasc Med. 2020 04; 30(3):179-185.
    View in: PubMed
    Score: 0.096
  6. Warden BA, Minnier J, Watts GF, Fazio S, Shapiro MD. Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. J Clin Lipidol. 2019 Jul - Aug; 13(4):580-585.
    View in: PubMed
    Score: 0.096
  7. Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 02 19; 8(4):e010932.
    View in: PubMed
    Score: 0.094
  8. Kaufman TM, Warden BA, Minnier J, Miles JR, Duell PB, Purnell JQ, Wojcik C, Fazio S, Shapiro MD. Application of PCSK9 Inhibitors in Practice. Circ Res. 2019 01 04; 124(1):32-37.
    View in: PubMed
    Score: 0.094
  9. Shapiro MD, Tavori H, Fazio S. PCSK9: From Basic Science Discoveries to Clinical Trials. Circ Res. 2018 05 11; 122(10):1420-1438.
    View in: PubMed
    Score: 0.090
  10. Shapiro MD, Miles J, Tavori H, Fazio S. Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. Ann Intern Med. 2018 03 06; 168(5):376-379.
    View in: PubMed
    Score: 0.087
  11. Shapiro MD, Fazio S. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Circ Res. 2016 Feb 19; 118(4):732-49.
    View in: PubMed
    Score: 0.077
  12. Shapiro MD, Sarwar A, Nieman K, Nasir K, Brady TJ, Cury RC. Cardiac computed tomography for prediction of myocardial viability after reperfused acute myocardial infarction. J Cardiovasc Comput Tomogr. 2010 Jul-Aug; 4(4):267-73.
    View in: PubMed
    Score: 0.052
  13. Board C, Kelly MS, Shapiro MD, Dixon DL. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy. J Cardiovasc Pharmacol. 2020 05; 75(5):410-420.
    View in: PubMed
    Score: 0.026
  14. Duell PB, Gidding SS, Andersen RL, Knickelbine T, Anderson L, Gianos E, Shrader P, Kindt I, O'Brien EC, McCann D, Hemphill LC, Ahmed CD, Martin SS, Larry JA, Ahmad ZS, Kullo IJ, Underberg JA, Guyton J, Thompson P, Wilemon K, Roe MT, Rader DJ, Cuchel M, Linton MF, Shapiro MD, Moriarty PM, Knowles JW. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. Atherosclerosis. 2019 10; 289:85-93.
    View in: PubMed
    Score: 0.024
  15. deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
    View in: PubMed
    Score: 0.019
  16. Jesin M, Rashewsky S, Shapiro M, Tobler W, Agarwal S, Burke P, Salama A. Predictors of mortality, hospital utilization, and the role of race in outcomes in head and neck trauma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jan; 121(1):12-6.
    View in: PubMed
    Score: 0.018
  17. Rogers IS, Cury RC, Blankstein R, Shapiro MD, Nieman K, Hoffmann U, Brady TJ, Abbara S. Comparison of postprocessing techniques for the detection of perfusion defects by cardiac computed tomography in patients presenting with acute ST-segment elevation myocardial infarction. J Cardiovasc Comput Tomogr. 2010 Jul-Aug; 4(4):258-66.
    View in: PubMed
    Score: 0.013
  18. Patel AG, Clark T, Oliver R, Stecker EC, Shapiro MD, Stajduhar K, Kron J, McAnulty JH, Chugh SS. Anomalous midline common ostium of the left and right inferior pulmonary veins: implications for pulmonary vein isolation in atrial fibrillation. Circ Arrhythm Electrophysiol. 2008 Dec; 1(5):407-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.